In May 11, 2023, Takeda reported a strong revenue and profit growth. Takeda has 5 major business areas, and they delivered reported revenue of 1,594.8 billion yen. Here are the 5 business areas:
- Gastroenterology (GI), with 1,094.5 billion yen in reported revenue, grew 8.7% on a CER basis driven by ENTYVIO®. ENTYVIO® is designed for treating ulcerative colitis (UC) and Crohn’s disease (CD)), and it is expanding through continued launches of the subcutaneous formulation, and in the U.S. is one of the first considered biologics for inflammatory bowel disease (UC and CD combined. ENTYVIO is available for intravenous infusion of 300 mg vedolizumab, and subcutaneous injection of 108 mg vedolizumab.
- Rare Diseases, with 723.4 billion yen in reported revenue, grew 4.8% on a CER basis. Sales of TAKHZYRO®.TAKHZYRO® is used for treating hereditary angioedema (HAE)) grew 25% on a CER basis, primarily due to expansion of the prophylactic market, continued geographic expansion and strong patient demand. Sales of LIVTENCITY® which is used for post-transplant cytomegalovirus infection/disease were 10.5 billion yen, driven by the strong launch momentum in the U.S. and geographic expansion in Europe.
TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent
attacks of hereditary angioedema (HAE) in people 2 years of age and
older. People with hereditary angioedema (HAE) don’t have enough C1-inhibitor protein, or the C1-inhibitor
protein doesn’t work properly. This causes plasma
kallikrein to become overactive. This increase in kallikrein activity
results in too much bradykinin, the substance that causes HAE attacks.
TAKHZYRO reduces kallikrein activity. LIVTENCITY is an oral tablet, its strength is 200 mg. Its active ingredient is maribavir.
- Plasma-Derived Therapies (PDT) Immunology, with 678.4 billion yen in reported revenue, delivered outstanding growth of 15.3% on a CER basis. Growth was driven by higher sales of immunoglobin products which are used for primary immunodeficiency, multifocal motor neuropathy and subcutaneous immunoglobin therapies, it has 16% growth on a CER basis. Robust growth for albumin products (mainly used for hypovolemia and hypoalbuminemia), at 19% on a CER basis. They have a strong demand in the U.S. and China.
- Oncology, with 438.7 billion yen in reported revenue, declined 14.4% on a CER basis as a result of generic competition that began in the U.S. in May 2022. Besides VELCADE, all other revenue totaled 411.0 billion yen, a year-over-year increase of 5% on a CER basis, mainly driven by ADCETRIS® (for malignant lymphomas), which grew 14% on a CER basis, due to growth in Argentina, Italy, and Japan. ALUNBRIG® (for non-small cell lung cancer) also grew 35% on a CER basis with strong demand in Europe, China, and other Markets. During FY2022, EXKIVITY® was approved for EGFR exon20 insertion+ non-small cell lung cancer in China.
VELCADE is an injectable product, its rout is intravenous, subcutaneous. Its strength is 1.5 mg/vial. VELCADE's active ingredient is bortezomib. ADCETRIS is a prescription medicine directed against the CD30 protein. ADCETRIS is given as an intravenous (IV) infusion, usually at an outpatient clinic. Its active ingredient is brentuximab vedotin. ALUNBRIG is an oral tablet. It has strengths of 30, 90 and 180 mg. Its active ingredient is brigatinib. EXKIVITY is an oral capsule. Its strength is 40 mg base. Its active ingredient is mobocertinib succinate.
- Neuroscience, with 637.7 billion yen in reported revenue, grew 12.1% on a CER basis, driven by increased adult ADHD demand for VYVANSE® in the North America and Europe for VYVANSE/ELVANSE. VYVANSE® are formulated into capsules and chewable tablets. Sales of TRINTELLIX grew at 2% on a CER basis due to strong market share gains in Japan, while demand in the U.S. grew in line with the anti-depressant market growth. TRINTELLIX is formulated in tablet only.
The drug lisdexamfetamine dimesylate (or lisdexamfetamine, trade name EU: Elvanse, U.S.: Vyvanse) has been approved in Germany since March 2013 for the treatment of attention deficit hyperactivity disorder (ADHD) in children from the age of 6 years. It is considered as a treatment option if previous treatment with the drug methylphenidate was unsuccessful.
Its approval was expanded in February 2019: Lisdexamfetamine (trade name: Elvanse Adult) can now also be used in adults who have had ADHD symptoms since childhood.
